Krawitz, Institute for Genomic Statistics and Bioinformatics, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud Street 25, 53127 Bonn, Germany. The distinct and rather peculiar characteristics of paroxysmal nocturnal hemoglobinuria (PNH) have puzzled hematologists for more than a century. HS, PMK, and TK contributed equally to this paper.Īddress correspondence to: Taroh Kinoshita, Yabumoto Department of Intractable Disease Research, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan. The primary clinical manifestations of paroxysmal nocturnal hemoglobinuria (PNH) are hemolytic anemia, marrow failure, and thrombophilia. Phone: 49.731.150.550 Email: note: BH, YM, and MO contributed equally to this paper. paroxysmal nocturnal hemoglobinuria, leukemia, immunologic disorders.
Phone: 49.228.287.14799 Email: Or to: Hubert Schrezenmeier, Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Helmholtzstrasse 10, 89081 Ulm, Germany. Finally, there were no data on smoking habits or other potential confounding. Krawitz, Institute for Genomic Statistics and Bioinformatics, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud Street 25, 53127 Bonn, Germany. 1Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.ĢInstitute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm, Germany.ģResearch Institute for Microbial Diseases andĤWPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.ĥDepartment of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.ĦInstitute for Genomic Statistics and Bioinformatics, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.ħDepartment of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan.ĨDepartment of Tumor Immunology, Osaka International Cancer Institute, Osaka, Japan.ĩDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.ġ0Institute for Human Genetics,Medical Faculty, RWTH University Aachen, Aachen, Germany.ġ1Department of Medical Genetics, Charite Hospital, University of Berlin, Berlin, Germany.ġ2MLL Muenchner Leukaemielabor GmbH, Munich, Germany.Īddress correspondence to: Taroh Kinoshita, Yabumoto Department of Intractable Disease Research, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan.
0 kommentar(er)
